✕
Login
Register
Back to News
Reported Earlier, Organogenesis Reports PuraPly AM Meets Primary Endpoint In Randomized Controlled Trial, Demonstrating Statistically Significant DFU Wound Closure At 12 Weeks
Benzinga Newsdesk
www.benzinga.com
Positive 95.3%
Neg 0%
Neu 0%
Pos 95.3%
Statistically significant (p<0.0477) DFU wound closure at 12 weeks
RCT compared PuraPly®AM plus standard of care to standard of care alone
Results strengthen existing clinical evidence supporting future coverage
Comments
No comments yet. Be the first!
Join the discussion
Login to comment
Login to comment